Capricor Therapeutics was founded in 2005 and is headquartered in Beverly Hills, US
Capricor Therapeutics Office Locations
Capricor Therapeutics has an office in Beverly Hills
Beverly Hills, US (HQ)
8840 Wilshire Blvd
Capricor Therapeutics Data and Metrics
Capricor Therapeutics Financial Metrics
Capricor Therapeutics's revenue was reported to be $4 m in 2016
Numbers are in $, USD
Revenue (Y, 2016) | 4 m |
Revenue growth (Y, 2015 - Y, 2016), % | (28%) |
Net income (Y, 2016) | (18.8 m) |
EBIT (Y, 2016) | (17 m) |
Market capitalization (22-Jun-2017) | 15.3 m |
Closing share price (22-Jun-2017) | 0.7 |
Cash (31-Dec-2016) | 3.2 m |
Capricor Therapeutics's current market capitalization is $15.3 m.
| Numbers are in $, USD | FY, 2013 | FY, 2014 | FY, 2015 | Y, 2016 |
|---|---|---|---|---|
Revenue | 503.2 k | 4.8 m | 5.5 m | 4 m |
Revenue growth, % | 851% | 15% | (28%) | |
R&D expense | 5.2 m | |||
General and administrative expense | 2.2 m | |||
Operating expense total | 7.4 m | 10.8 m | 18.1 m | 21 m |
EBIT | (6.9 m) | (6 m) | (12.6 m) | (17 m) |
EBIT margin, % | (1372%) | (126%) | (229%) | (425%) |
Interest expense | 58.1 k | 200.5 k | 248.6 k | 344.7 k |
Net Income | (8.9 m) | (6.2 m) | (12.9 m) | (18.8 m) |
| Numbers are in $, USD | FY, 2013 | FY, 2014 | FY, 2015 | FY, 2016 |
|---|---|---|---|---|
Cash | 1.7 m | 8 m | 5.6 m | 3.2 m |
Accounts Receivable | 187 | |||
Inventories | 222.8 k | 235.5 k | 210.6 k | 342.9 k |
Current Assets | 3.7 m | 11.6 m | 14 m | 18.1 m |
PP&E | 229.5 k | 318.6 k | 435.3 k | |
Total Assets | 5.5 m | 13.6 m | 16.1 m | 18.7 m |
Accounts Payable | 1.5 m | 1.7 m | 2.5 m | 3 m |
Current Liabilities | 2.1 m | 6.3 m | 6.5 m | 4.9 m |
Non-Current Liabilities | 4 m | 13.6 m | 10.6 m | 17.9 m |
Total Liabilities | 6.1 m | 19.9 m | 17.1 m | 22.8 m |
Additional Paid-in Capital | 15.6 m | 16.1 m | 34.1 m | 50 m |
Retained Earnings | (22.3 m) | (35.2 m) | (54 m) | |
Total Equity | (534.9 k) | (6.2 m) | (1 m) | (4 m) |
Financial Leverage | -10.4 x | -2.2 x | -15.6 x | -4.7 x |
| Numbers are in $, USD | FY, 2013 | FY, 2014 | FY, 2015 | FY, 2016 |
|---|---|---|---|---|
Net Income | (8.9 m) | (6.2 m) | (12.9 m) | (18.8 m) |
Depreciation and Amortization | 26.9 k | 41.9 k | 110.9 k | 125.7 k |
Accounts Receivable | 25 k | |||
Inventories | (161.6 k) | (12.6 k) | 24.9 k | (132.3 k) |
Accounts Payable | 974.7 k | 70.3 k | 831.2 k | 508.3 k |
Cash From Operating Activities | (6.1 m) | 958.6 k | (10.8 m) | (15.8 m) |
Purchases of PP&E | (186.4 k) | (129.7 k) | (192 k) | |
Cash From Investing Activities | 3.8 m | 141 k | (8.1 m) | (5.2 m) |
Cash From Financing Activities | 3.9 m | 5.2 m | 16.5 m | 18.6 m |
| Numbers are in $, USD | Y, 2016 |
|---|---|
Revenue/Employee | 137.9 k |
Financial Leverage | -4.7 x |
